Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Transthyretin Amyloidosis | ATTR-CM | hATTR | ATTR-Mixed | ATTR | ATTRv-PNThe MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 and up
Participation Criteria
Inclusion Criteria:
* Patient willing and able to provide written informed consent to participate in the study
* Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis
* Aged ≥18 years at the time of signing the informed consent
* Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)
Exclusion Criteria:
* Concurrent participation in any interventional trial for ATTR amyloidosis
* Involvement in the planning and/or conduct of the current study
* Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)
* Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers
Study Location
Research Site
Research SiteHalifax, Nova Scotia
Canada
Contact Study Team
Research Site
Research SiteVancouver, British Columbia
Canada
Contact Study Team
Research Site
Research SiteLondon, Ontario
Canada
Contact Study Team
Research Site
Research SiteToronto, Ontario
Canada
Contact Study Team
- Study Sponsored By
- AstraZeneca
- Participants Required
- More Information
- Study ID:
NCT06465810